Latest Scheme Of Arrangement News

Aston Minerals Limited held crucial shareholder and optionholder meetings to approve its merger with Torque Metals Limited, marking a significant step toward consolidation in the minerals exploration sector.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

New World Resources Limited has entered a binding agreement for acquisition by Central Asia Metals Plc at a significant premium, valuing the company at approximately A$185 million. The transaction, unanimously recommended by New World’s board, is set to complete by September 2025, subject to shareholder and court approvals.

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ assertion of a Material Adverse Change that could derail their acquisition scheme, insisting the deal process continues as planned.

Gold Road Resources has secured a crucial regulatory green light as the Foreign Investment Review Board approves Gold Fields’ acquisition scheme. The deal now moves closer to shareholder and court approvals.

Mayne Pharma has sent out the Scheme Booklet to shareholders, marking a key step in the proposed acquisition by Cosette. The booklet includes critical details to guide shareholder decisions ahead of the upcoming Scheme Meeting.

NSX Limited has entered a Scheme Implementation Deed with CNSX Markets Inc. for a full acquisition at a 59% premium, subject to shareholder and regulatory approvals. The deal aims to strengthen NSX’s market position and expand its product offerings.

Contact Energy Limited has announced a court-approved scheme to acquire Manawa Energy Limited, offering Manawa shareholders $1.12 cash plus 0.5830 new Contact shares per share, representing a significant premium. The merger aims to create a diversified renewable energy portfolio with substantial synergies and growth prospects.

The Reject Shop Limited has entered a recommended scheme of arrangement with Dollarama Inc., offering shareholders $6.68 cash per share, a substantial premium over recent trading prices. The Independent Expert deems the deal fair and reasonable, with a shareholder meeting set for June 23.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.

Peak Rare Earths is poised for acquisition by Shenghe Resources in a deal valuing the company at A$150.5 million, supported by a A$7.5 million entitlement offer to fund ongoing development and transaction costs.

Peak Rare Earths Limited has agreed to be acquired by Ganzhou Chenguang Rare Earths New Material Co., Ltd., a subsidiary of Shenghe Resources, in a deal valuing Peak at A$150.5 million plus proceeds from a proposed entitlement offer. The transaction offers Peak shareholders a significant premium and aims to accelerate development of the Ngualla Rare Earth Project.